echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > J Autoimmun: SARS-CoV-2 infection in patients with autoimmune rheumatoid disease in north-eastern Italy.

    J Autoimmun: SARS-CoV-2 infection in patients with autoimmune rheumatoid disease in north-eastern Italy.

    • Last Update: 2020-08-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    It is not clear whether patients with autoimmune rheumatoid disease (ARD) have a high risk of SARS-CoV-2 infection (COVID-19), and the impact of the SARS-CoV-2 pandemic on patients' treatment compliance.
    recently, researchers assessed the rate and clinical manifestations of COVID-19 in a large number of ARD follow-up patients at Northeastern University Hospital in Italy, and their findings were published online at J Autoimmun.
    Between April 9 and April 25, 2020, after the peak of SARS-CoV-2 infection, researchers conducted a telephone survey to investigate the effects of COVID-19 on patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), ANCA-related vasculitis (AAV) and adrenal inflammatory myopathy (IIM).
    addition, the researchers collected demographics, disease activity status, treatment, occupational exposure, and compliance with remote social alienation recommendations.
    results, 916 patients (397 SLE, 182 AAV, 176 SSc, 111 RA, 50 IIM) completed the survey.
    148 patients developed at least one symptom associated with COVID-19 (cough 96 cases, sore throat 64 cases, fever 64 cases, arthritis 59 cases, diarrhea 26 cases, conjunctivitis 18 cases, Alzheimer's disease / sweating disease 18 cases).
    of the 916 patients, 65 (7.1 per cent) were tested for SARS-CoV-2 nasopharyngeal swabs (18 had symptoms and 47 were asymptomatic), of which 2 (0.21 per cent) tested positive, a similar proportion to the general population in the Venito region.
    no deaths have occurred.
    31 patients (3.4%) withdrew from more than 1 drug, mainly immunosuppressants or biologics.
    860 patients (93.9 per cent) were socially alienated, of whom 335 (36.6 per cent) were used before the formal closure.
    , the results show that the rate of COVID-19 in the study queue appears to be similar compared to the general population.
    are highly dependent on treatment and social alienation recommendations.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.